- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02054858
Preconditioning Against Renal Damage Under Contrast Examination (Re-DUCE-F)
Preconditioning Against Renal Damage Under Contrast Examination: a Single Centre, Randomized, Sham -Controlled Clinical Feasibility Trial
This study aims to assess if applying an ischaemic insult to an arm before giving intravenous contrast will help decrease the incidence of developing contrast induced acute renal injury in patients undergoing contrast-enhanced CT Scans.
The main research question is 'In adult in-patients undergoing contrast-enhanced CT scans, does remote ischaemic pre-conditioning (RIPC) induced by brief arm ischaemia and reperfusion, when compared to control, reduce the proportion of patients developing contrast-induced acute kidney injury in the first 3 post-scan days? '.
Study Overview
Detailed Description
Intravenous contrast for diagnostic and therapeutic interventions is a leading cause of hospital-acquired acute renal failure (1). Contrast-induced acute kidney injury (CI-AKI) occurs through a complex mechanism including toxic and hypoxic renal tubular injury, diminished renal parenchymal circulation and renal endothelial dysfunction with the production of oxygen free radicals due to post-ischaemia oxidative stress (2). With increasing numbers of diagnostic and therapeutic interventions, the incidence of CI-AKI will rise over the next few decades. Already, 40% of general surgical in-patients undergo cross-sectional imaging with computed tomography (CT), largely using contrast (3). Optimal clinical care in many specialties such as oncology, emergency medicine and surgery relies upon information derived from contrast-enhanced cross-sectional imaging. In consequence, large numbers of patients are exposed to the risk of CI-AKI. Current CI-AKI preventive measures comprise identification of at-risk patients, minimisation of contrast dose and the use of intravenous volume expansion (4). Simple, cost-effective methods to reduce CI-AKI are required.
Risk factors for CI-AKI include advanced age, diabetes mellitus, pre-existing renal insufficiency and congestive cardiac failure. Dehydration also increases the risk (5). While patients over the age of 65 years currently account for 11% of the Irish population, they account for 30% of surgical admissions (6). In a recent cohort study of 1800 surgical in-patients in a major Irish teaching hospital, acute renal failure was a common major complication, occurring in 2.4% of patients (6). Multivariate analysis of this cohort demonstrated that increasing age and emergency admission were both independent risk factors for complications (6). Emergency surgical patients constitute a high-risk group in whom simple methods to minimise complications are required.
Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues e.g. heart or kidney (7). It reduces renal damage following endovascular aneurysm repair, a procedure requiring considerable contrast-volumes (8). A recent meta-analysis demonstrated that RIPC significantly reduced post-procedure creatinine levels following cardiovascular procedures, though there was considerable clinical heterogeneity between the included trials (9). We hypothesise that RIPC induced using brief periods of upper limb ischaemia-reperfusion will reduce AKI in patients undergoing contrast enhanced CT scans.
The hypothesis that RIPC will reduce CI-AKI was first explored by Whittaker and Pryzklenk (10). They utilised available data from a patient cohort undergoing emergency coronary angioplasty. Patients with 1 to 3 balloon inflations in the coronary artery served as the control group whilst those with >3 balloon inflations served as the RIPC group.Both groups displayed an immediate improvement in estimated glomerular filtration rate (eGFR). However, the control group then displayed a statistically significant decrease in eGFR by day 3 post-procedure (77 +14 ml/min/1.73m2 versus 70 +12 ml/min/1.73m2). The RIPC group displayed no such difference by day 3 (81 +21 ml/min/1.73m2 versus 80 +14 ml/min/1.73m2) despite having received a larger contrast volume. This observation implied a potential protective effect for RIPC.
Greater availability of CT technology has led to a dramatic increase in the number of patients undergoing ce-CTAP in recent years. Between 1996 and 2010, the number of patients undergoing CT scans in the United States tripled, increasing by 8% per annum (11). Simultaneously, an increasingly elderly and sick population means that many patients now have multiple co-morbidities, increasing their risk of contrast-induced acute kidney injury. Approximately 6.5% of patients undergoing ce-CT develop acute kidney injury defined as a >25% increase in serum creatinine from baseline (12). Simple methods to reduce CI-AKI are required. We propose that the use of remote ischaemic preconditioning could be a simple, cost-effective measure that could decrease the incidence of CI-AKI in high risk patients undergoing contrast enhanced CT scans.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mary Clarke Moloney, PhD
- Phone Number: 00353 61482736
- Email: mary.clarkemoloney@hse.ie
Study Locations
-
-
-
Limerick, Ireland, 00
- Recruiting
- University Hospital Limerick
-
Contact:
- Mary Clarke Moloney, PhD
- Phone Number: 00353 61482736
- Email: mary.clarkemoloney@hse.ie
-
Contact:
- Kamsila Pillay, MBChB, MRCS
- Phone Number: 003530877429483
- Email: kamsilakp@yahoo.co.uk
-
Principal Investigator:
- Stewart R Walsh, MCh FRCS
-
Sub-Investigator:
- Kamsila Pillay, MBChB, MRCS
-
Sub-Investigator:
- Mary Clarke Moloney, PhD
-
Sub-Investigator:
- John Forbes, MSc PhD
-
Sub-Investigator:
- Austin Stack, MD MSc FRCPI
-
Sub-Investigator:
- Philip Hodnett
-
Sub-Investigator:
- Tim Scanlon
-
Sub-Investigator:
- Walter Cullen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All medical and surgical in-patients aged 40-yrs or over scheduled to undergo contrast-enhanced CT scans.
- Patients willing to give full informed consent for participation
Exclusion Criteria:
- Pregnancy
- Significant upper limb peripheral arterial disease
- Previous history of upper limb deep vein thrombosis
- Patients on glibenclamide or nicorandil (these medications may interfere with RIPC)
- Patients with an estimated pre-operative glomerular filtration rate <30mls/min/1.73m2
- Patients with a known history of myocarditis, pericarditis or amyloidosis
- Patients who have received intravenous contrast in the previous year
- Patients with severe hepatic disease defined as a an international normalised ratio >2 in the absence of systemic anticoagulation
- Patients previously enrolled in the trial representing a further scan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: RIPC
Preconditioning will be performed in the same manner as several previous trials.
Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
|
Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg.
heart or kidney.
In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan.
A CE-approved blood pressure cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
Other Names:
|
NO_INTERVENTION: Control
Patients randomised to this group will receive routine care associated with undergoing a CT scan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in estimated glomerular filtration rate(eGFR) using RIPC
Time Frame: 3 days post scan
|
Our primary research objective is to determine whether RIPC induced using brief arm ischaemia and reperfusion reduces the proportion of patients who develop a reduction in estimated glomerular filtration rate(eGFR) ≥20% in the first 3 days following CT scan
|
3 days post scan
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of hospital stay
Time Frame: 30 days
|
To determine whether RIPC reduces length of hospital stay
|
30 days
|
Length of intensive care stay
Time Frame: 30 days
|
To determine whether RIPC reduces ITU stay
|
30 days
|
Numbers of unplanned critical care admissions
Time Frame: 30 days
|
To determine whether RIPC reduces unplanned critical care admission
|
30 days
|
Renal impariment after 1 year
Time Frame: 1 year
|
To determine the proportion of patients who develop renal impairment within 1 year of ce-CT
|
1 year
|
Recruitment potential for phase 3 study
Time Frame: 15 months
|
To evaluate the likely recruitment rates for a phase 3 trial
|
15 months
|
Acceptability of intervention
Time Frame: 30 days
|
To examine the acceptability of the intervention to clinicians and patients utilising qualitative methods
|
30 days
|
Cost effectiveness
Time Frame: 1 year
|
To evaluate the cost-effectiveness of RIPC in the prevention of CI-AKI in patients undergoing ce-CT
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stewart R Walsh, MCh FRCS, University Hospital of Limerick
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Preconditioning-ReDUCE-F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
-
University Hospital MuensterBaxter Healthcare CorporationCompletedAcute Kidney Injury (AKI)Spain, France, United States, Turkey, Germany, Egypt, Italy, Libyan Arab Jamahiriya, Malta, North Macedonia, Palestinian Territory, occupied, Russian Federation, Saudi Arabia, Slovenia
-
Chinese PLA General HospitalBeijing Tsinghua Changgeng HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Chinese PLA General HospitalCompletedPostoperative Acute Kidney InjuryChina
-
Ain Shams UniversityRecruiting
-
Astellas Pharma IncCompleted
-
South Egypt Cancer InstituteCompletedAcute Kidney Injury (AKI)Egypt
Clinical Trials on RIPC
-
Helsinki University Central HospitalAcademy of Finland; Finska Läkaresällskapet (funding); Helsinki University Hospital...Recruiting
-
Oladipupo Olafiranye, MD, MSNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingContrast-induced Acute Kidney InjuryUnited States
-
Liverpool John Moores UniversityCompletedCardiovascular Disease RiskUnited Kingdom
-
Westfälische Wilhelms-Universität MünsterRecruitingSepsis | Acute Kidney Injury | Critically IllGermany
-
Seoul National University HospitalCompletedIschemic Reperfusion Injury | Radiotherapy | Other Reconstructive SurgeryKorea, Republic of
-
Seoul National University HospitalCompletedRemote Ischemic PreconditioningKorea, Republic of
-
Fundación Centro Nacional de Investigaciones Cardiovasculares...European CommissionRecruitingLymphoma | Anthracycline-induced Cardiac ToxicityNetherlands, Spain, Denmark, Germany, France, Portugal
-
Shanghai Zhongshan HospitalCompletedCardiac SurgeryChina
-
Changi General HospitalUniversity College Hospital GalwayCompletedContrast Induced Nephropathy | Remote Ischaemic PreconditioningSingapore
-
Mid Western Regional Hospital, IrelandUnknownPeripheral Vascular DiseaseIreland